ATE476176T1 - Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung - Google Patents

Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung

Info

Publication number
ATE476176T1
ATE476176T1 AT08743631T AT08743631T ATE476176T1 AT E476176 T1 ATE476176 T1 AT E476176T1 AT 08743631 T AT08743631 T AT 08743631T AT 08743631 T AT08743631 T AT 08743631T AT E476176 T1 ATE476176 T1 AT E476176T1
Authority
AT
Austria
Prior art keywords
sustained
tablets containing
release tablets
containing wax
pellets
Prior art date
Application number
AT08743631T
Other languages
English (en)
Inventor
Andrew Chen
Patricia Kigin
Original Assignee
Farnam Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farnam Co Inc filed Critical Farnam Co Inc
Application granted granted Critical
Publication of ATE476176T1 publication Critical patent/ATE476176T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pest Control & Pesticides (AREA)
  • Dentistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Agronomy & Crop Science (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT08743631T 2007-03-02 2008-02-29 Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung ATE476176T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90445607P 2007-03-02 2007-03-02
PCT/US2008/055534 WO2008109462A2 (en) 2007-03-02 2008-02-29 Sustained release pellets comprising wax-like material

Publications (1)

Publication Number Publication Date
ATE476176T1 true ATE476176T1 (de) 2010-08-15

Family

ID=39649304

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08743631T ATE476176T1 (de) 2007-03-02 2008-02-29 Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung

Country Status (10)

Country Link
US (2) US10888521B2 (de)
EP (1) EP2144599B1 (de)
JP (3) JP5452236B2 (de)
CN (1) CN101652128B (de)
AT (1) ATE476176T1 (de)
AU (1) AU2008223091B2 (de)
CA (1) CA2678367C (de)
DE (1) DE602008002073D1 (de)
ES (1) ES2350029T3 (de)
WO (1) WO2008109462A2 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
ITPD20070274A1 (it) * 2007-08-08 2009-02-09 Sanypet S P A Crocchetta per animali e metodo per la sua produzione
NZ586792A (en) 2008-01-25 2012-09-28 Gruenenthal Chemie Tamper resistant controlled release pharmaceutical tablets form having convex and concave surfaces
RU2508092C2 (ru) 2008-05-09 2014-02-27 Грюненталь Гмбх Способ получения твердой лекарственной формы, в частности таблетки для фармацевтического применения, и способ получения прекурсора твердой лекарственной формы, в частности таблетки
PL2456424T3 (pl) 2009-07-22 2013-12-31 Gruenenthal Gmbh Stabilizowana przed utlenianiem odporna na naruszenie postać dawkowania
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
WO2011080570A2 (en) * 2009-12-29 2011-07-07 Micro Labs Limited Extended release pharmaceutical composition comprising linezolid and process for preparing the same
WO2011095314A2 (en) 2010-02-03 2011-08-11 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
IT1398321B1 (it) * 2010-02-26 2013-02-22 Formevet Spa Ora Formevet Srl Associazione tra un analgesico ad azione centrale e un antinfiammatorio inibitore selettivo della cicloossigenasi 2 per il trattamento dell'infiammazione e del dolore in campo veterinario
PL2611425T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Odporna na ingerencję postać dawki zawierająca polimer anionowy
PE20131102A1 (es) 2010-09-02 2013-10-12 Gruenenthal Chemie Forma de dosificacion resistente a manipulacion que comprende una sal inorganica
US20120107393A1 (en) * 2010-10-29 2012-05-03 University Of Tennessee Research Foundation Pellets for Delivery of Biologically Active Substances
LT3400944T (lt) 2010-11-04 2020-09-25 Albireo Ab Ibat inhibitoriai, skirt kepenų ligų gydymui
NO2736497T3 (de) 2011-07-29 2018-01-20
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
CN102440963A (zh) * 2011-11-29 2012-05-09 北京科信必成医药科技发展有限公司 一种别嘌醇缓释微丸及其制备方法
EP2785333A4 (de) 2011-12-02 2015-04-01 Pegasus Lab Inc Amphipatische zusammensetzungen mit verzögerter freisetzung auf lipidbasis
US10722458B2 (en) 2011-12-02 2020-07-28 Pegasus Laboratories, Inc. Amphipathic lipid-based sustained release compositions
CN102716090B (zh) * 2012-01-05 2014-07-16 金陵药业股份有限公司 一种盐酸二甲双胍缓释微丸及其制备方法
CN102590410A (zh) * 2012-01-13 2012-07-18 亚宝药业太原制药有限公司 盐酸氨基葡萄糖胶囊的含量测定方法
CN102579405A (zh) * 2012-01-17 2012-07-18 广州科的信医药技术有限公司 一种盐酸噻氯匹定缓释胶囊及其制备方法
ES2769924T3 (es) 2012-02-06 2020-06-29 Innovative Med Concepts Llc Compuesto antiviral y terapia de combinación de inhibidores de la COX-2 para la fibromialgia
WO2013127831A1 (en) 2012-02-28 2013-09-06 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
DK2838512T3 (en) 2012-04-18 2018-11-19 Gruenenthal Gmbh MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
US9849088B2 (en) 2012-05-10 2017-12-26 Painreform Ltd. Depot formulations of a hydrophobic active ingredient and methods for preparation thereof
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN102743341B (zh) * 2012-07-28 2014-02-26 西安德天药业股份有限公司 右旋酮洛芬氨丁三醇缓释微粒及其制备方法和缓释制剂
CN103860551A (zh) * 2012-12-10 2014-06-18 鲁南制药集团股份有限公司 含有依托度酸和盐酸曲马多的药物组合物及其应用
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
US9630909B2 (en) 2013-06-27 2017-04-25 Mylan Laboratories Ltd Process for the preparation of nepafenac
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
CN103432082A (zh) * 2013-08-29 2013-12-11 江苏正大清江制药有限公司 氨基葡萄糖组合物及其制备方法
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
EP3125873B1 (de) 2014-04-04 2020-06-03 Pharmaquest International Center, LLC Zerfallende monolithische tabletten mit modifizierter freisetzung mit quadri-schichtgranulaten mit verlängerter freisetzung
CN106572980A (zh) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 包含他喷他多的防篡改即释胶囊制剂
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
KR102560954B1 (ko) 2014-06-25 2023-07-31 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
MA41124A (fr) * 2014-12-05 2017-10-10 Sun Pharmaceutical Ind Ltd Compositions en suspension à libération prolongée à rétention gastrique
CN105982860B (zh) * 2015-02-11 2020-04-14 北京科信必成医药科技发展有限公司 愈创甘油醚无水吞服掩味颗粒
MX2017013637A (es) 2015-04-24 2018-03-08 Gruenenthal Gmbh Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes.
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
JP2019523275A (ja) * 2016-07-26 2019-08-22 アナンド パラチュル，ヴィヴェク 有効成分の徐放性組成物
WO2018031935A1 (en) 2016-08-11 2018-02-15 Adamis Pharmaceuticals Corporation Drug compositions
JP2020530448A (ja) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
EP3459527B1 (de) 2017-09-20 2022-11-23 Tillotts Pharma Ag Verfahren zur herstellung einer festen dosierungsform mit antikörpern durch nassgranulation, -extrusion und -sphäronisierung
CN107802610B (zh) * 2017-11-22 2020-10-20 乐普药业股份有限公司 一种单硝酸异山梨酯缓释片及制备方法
EP3720844A4 (de) 2017-12-08 2021-08-11 Adamis Pharmaceuticals Corporation Arzneimittelzusammensetzungen
US11471386B2 (en) 2017-12-29 2022-10-18 Conopco, Inc. Non-spherical microcapsule
CN111542303B (zh) 2017-12-29 2023-07-25 联合利华知识产权控股有限公司 非球形微囊
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES2942443T3 (es) 2018-06-05 2023-06-01 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares
PE20210136A1 (es) 2018-06-20 2021-01-21 Albireo Ab Formulacion farmaceutica de odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
CN108578376A (zh) * 2018-07-27 2018-09-28 广州柏赛罗药业有限公司 性能改善的缓释微丸组合物
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
CN120154576A (zh) * 2018-08-31 2025-06-17 欧普科爱尔兰环球控股有限公司 儿童剂型、制造和使用方法
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
SMT202300020T1 (it) 2019-02-06 2023-03-17 Albireo Ab Composti di benzotiadiazepine e loro uso come modulatori degli acidi biliari
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
IT201900013449A1 (it) * 2019-07-31 2021-01-31 Vetagro Int S R L Composizione comprendente amminoacidi e una matrice lipidica per animali monogastrici non mammiferi e suo uso
IT201900013473A1 (it) * 2019-07-31 2021-01-31 Vetagro Int S R L Composizioni comprendenti amminoacidi e un ulteriore componente per l'apporto di amminoacidi ad un animale monogastrico quale uomo o maiale
CN110917144A (zh) * 2019-11-30 2020-03-27 江苏艾兰得营养品有限公司 一种骨架型维生素c缓释微丸及其制备方法
ES2972045T3 (es) 2019-12-04 2024-06-10 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
JP7665620B2 (ja) 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
ES2973549T3 (es) 2019-12-04 2024-06-20 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores de los ácidos biliares
EP4069361B1 (de) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepinverbindungen und ihre verwendung als gallensäuremodulatoren
CN110898036A (zh) * 2019-12-18 2020-03-24 乐普制药科技有限公司 一种熊去氧胆酸缓释肠溶胶囊及其制备方法
ES3002777T3 (en) 2020-08-03 2025-03-07 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
KR20230106651A (ko) 2020-11-12 2023-07-13 알비레오 에이비 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트
CA3198216A1 (en) 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
GB2618161A (en) * 2020-12-25 2023-11-01 Nutriventia Ltd Stable prolonged release formulation of vitamin C and A process for preparation thereof
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
CN113791150B (zh) * 2021-09-09 2023-08-11 浙江公正检验中心有限公司 一种用于动物源性食品中头孢类药物残留量的检测方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3908028A (en) * 1973-04-19 1975-09-23 Procter & Gamble Soft drink composition containing paramethoxycinnamaldehyde as a flavoring agent and sweetner
US4166107A (en) * 1978-07-25 1979-08-28 The United States Of America As Represented By The Secretary Of Agriculture Sustained release bolus formulations containing insect growth regulators for control of livestock pests
GB2209669B (en) 1987-09-11 1992-02-12 Squibb & Sons Inc Pharmaceutical composition containing high drug load and method for preparing same
US4761450A (en) * 1987-12-11 1988-08-02 Baychem International, Inc. Compatible polymer blends useful as melt adhesives
JP2760012B2 (ja) 1988-12-26 1998-05-28 武田薬品工業株式会社 持続性細粒剤
JPH02193914A (ja) 1989-01-23 1990-07-31 Sumitomo Pharmaceut Co Ltd マトリックス型持続性製剤
GB8913889D0 (en) * 1989-06-16 1989-08-02 May & Baker Ltd New compositions of matter
RU2111663C1 (ru) 1991-01-16 1998-05-27 Фмк Корпорейшн Твердая сыпучая композиция носителя для активного вещества в твердой дозированной вододиспергируемой форме, способ ее получения и твердая дозированная форма
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
BR9206996A (pt) * 1991-12-30 1995-12-05 Fmc Corp Composição adequada para preparar esferóides por esferoidização processo para produzir um material em partículas processo para produzir uma forma de dosagem de sólido esferoidizado em partículas e forma de dosagem sólida
SE9200858L (sv) * 1992-03-20 1993-09-21 Kabi Pharmacia Ab Metod för framställning av pellets med fördröjd frisättning
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US5582351A (en) * 1993-08-09 1996-12-10 Tsau; Josef Convenient to use aspartame and method of making
JP3776941B2 (ja) 1993-12-24 2006-05-24 塩野義製薬株式会社 味覚の改善された顆粒剤及びその製造方法
DE4413350A1 (de) * 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
US5582855A (en) * 1994-07-01 1996-12-10 Fuisz Technologies Ltd. Flash flow formed solloid delivery systems
DE69624559T2 (de) * 1995-02-28 2003-07-10 Aventis Pharmaceuticals Inc., Bridgewater Arzneizubereitungen für piperidinalkanolderivate
FR2742659B1 (fr) 1995-12-22 1998-03-13 Pf Medicament Procede de fabrication de minispheres matricielles a liberation prolongee
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
CA2241896A1 (en) 1996-11-01 1998-05-14 Ze'ev Shaked Sustained release formulation containing dfmo
CA2282531A1 (en) 1997-03-25 1998-10-01 Takeda Chemical Industries, Ltd. Gastrointestinal mucosa-adherent pharmaceutical composition
IL143002A0 (en) * 1998-11-12 2002-04-21 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
WO2001010405A1 (en) 1999-08-04 2001-02-15 Ranbaxy Laboratories Limited Hydrodynamically balanced oral drug delivery system
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6953593B2 (en) * 2000-02-01 2005-10-11 Lipoprotein Technologies, Inc. Sustained-release microencapsulated delivery system
DE60138706D1 (de) * 2000-02-08 2009-06-25 Euro Celtique Sa Missbrauchssichere orale opioid-agonist zubereitungen
US20020086070A1 (en) * 2000-03-11 2002-07-04 Kuhrts Eric Hauser Anti-inflammatory and connective tissue repair formulations
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
AU2001280597A1 (en) * 2000-07-17 2002-01-30 Guilford Pharmaceuticals Inc. Compositions for sustained release of analgesic agents, and methods of making and using the same
WO2002035991A2 (en) * 2000-10-30 2002-05-10 The Board Of Regents, The University Of Texas System Spherical particles produced by a hot-melt extrusion/spheronization process
US6620611B2 (en) * 2001-01-06 2003-09-16 Geovation Technologies, Inc. Solid-chemical composition for sustained release of organic substrates and complex inorganic phosphates for bioremediation
SK287902B6 (sk) * 2001-01-31 2012-03-02 Evonik Rohm Gmbh Multiparticulate drug form and method for the preparation thereof
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
EP1443912B1 (de) 2001-10-12 2007-08-29 Elan Pharma International Limited Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
JP2004024686A (ja) 2002-06-27 2004-01-29 Nippon Shinyaku Co Ltd 医薬ワックスマトリックスの製法
BR0312206A (pt) * 2002-06-27 2005-04-12 Cilag Ag Formulações de pélete esférico
CN1201736C (zh) * 2002-07-19 2005-05-18 安徽省药物研究所 甲硝唑结肠定位缓释制剂
US20040208936A1 (en) * 2002-07-22 2004-10-21 Roland Chorin Novel compositions
TWI357815B (en) 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005055972A2 (en) * 2003-12-09 2005-06-23 Nanon A/S A drug delivery device and a method of producing it
WO2006045152A1 (en) * 2004-10-29 2006-05-04 Mayne Pharma International Pty Ltd Improved tabletting process

Also Published As

Publication number Publication date
US10888521B2 (en) 2021-01-12
CN101652128B (zh) 2012-12-19
WO2008109462A2 (en) 2008-09-12
HK1141441A1 (en) 2010-11-12
EP2144599B1 (de) 2010-08-04
US20080220079A1 (en) 2008-09-11
CA2678367A1 (en) 2008-09-12
JP2014055158A (ja) 2014-03-27
US20210113469A1 (en) 2021-04-22
WO2008109462A3 (en) 2008-12-24
CA2678367C (en) 2014-07-08
JP2010520226A (ja) 2010-06-10
JP2016000728A (ja) 2016-01-07
AU2008223091B2 (en) 2014-04-24
AU2008223091A1 (en) 2008-09-12
DE602008002073D1 (de) 2010-09-16
EP2144599A2 (de) 2010-01-20
ES2350029T3 (es) 2011-01-17
JP5452236B2 (ja) 2014-03-26
CN101652128A (zh) 2010-02-17

Similar Documents

Publication Publication Date Title
ATE476176T1 (de) Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung
FR2949062B1 (fr) Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
CY1118040T1 (el) Συνθεσεις για πνευμονικη απελευθερωση μακροχρονιως-δρωντων μουσκαρινικων ανταγωνιστων και μακροχρονιως-δρωντων αγωνιστων β2 αδρενεργικων υποδοχεων και συσχετιζομενες μεθοδοι και συστηματα
AR114143A2 (es) Formulaciones de comprimidos revestidos
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
WO2009117130A3 (en) Extended release forumulation containing a wax
ECSP088560A (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
MX2009000320A (es) Formulaciones de liberacion controlada.
AR082493A1 (es) Formulaciones a base de nalbufina, y sus utilizaciones
WO2007067044A3 (en) Modified active-ingredient-containing pellets/capsules
MY149623A (en) Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation
AR065096A1 (es) Preparacion solida
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
UA88477C2 (ru) Композиция пеллеты пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
ZA200900929B (en) Microparticles based on an amphiphilic copolymer and on active ingredient(s) with modified release and pharmaceutical formulations containing same
BR112012024019A2 (pt) forma de dosagem de liberação controlada, e, método para liberar uma droga
SG157415A1 (en) Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
WO2006011159A3 (en) Stabilized pharmaceutical composition containing rabeprazole sodium with improved bioavailability
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
BRPI0814891A2 (pt) Composição farmacêutica contendo composto oticamente ativo tendo atividade agonista de receptor de trombopoietina, e intermediário do mesmo.
MX2012013021A (es) Formulaciones resistentes a alcohol.
UY35091A (es) Formulaciones de liberacion modificada para oprozomib
EA200900958A1 (ru) Препарат невирапина пролонгированного высвобождения

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties